This HTML5 document contains 38 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n9http://linked.opendata.cz/resource/drugbank/drug/DB05490/identifier/pubchem-compound/
n6http://bio2rdf.org/drugbank:
n11http://linked.opendata.cz/resource/drugbank/drug/DB05490/identifier/drugbank/
admshttp://www.w3.org/ns/adms#
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n10http://linked.opendata.cz/resource/drugbank/drug/DB05490/identifier/chemspider/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#

Statements

Subject Item
n2:DB05490
rdf:type
n3:Drug
n3:description
T131, an orally-administered therapy, is expected to lower blood glucose in type II diabetic patients by improving the body’s ability to respond to insulin. T131 is a selective modulator of PPARg (peroxisome proliferator activated receptor gamma), a receptor involved in regulating the body’s ability to respond to insulin. T131 is not structurally related to the thiazolidinedione class of PPARg agonists, which includes Actos and Avandia.
n3:group
investigational
n3:indication
Investigated for use/treatment in diabetes mellitus type 2.
owl:sameAs
n6:DB05490
dcterms:title
T131
adms:identifier
n9:16145453 n10:17301924 n11:DB05490
n3:mechanismOfAction
T131 is a selective modulator of PPARg (peroxisome proliferator activated receptor gamma), a receptor involved in regulating the body’s ability to respond to insulin. T131 is not structurally related to the thiazolidinedione class of PPARg agonists, which includes Actos and Avandia
n3:synonym
INT-131
n3:toxicity
In preclinical studies comparing T131 to Avandia, T131 demonstrated superior potency and an improved side effect profile. In these studies, T131 treatment did not result in fluid retention or cardiac hypertrophy. In Phase 1 studies with T131, all doses were well tolerated and no serious adverse events were observed.
n3:IUPAC-Name
n4:271B452A-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B4530-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B452F-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B452C-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B452D-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B452E-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B4528-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B4529-363D-11E5-9242-09173F13E4C5 n4:271B4526-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B4527-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B4536-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B4537-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B4531-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B4532-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B4534-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B4533-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B4535-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B453C-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B453E-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B453F-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B453B-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B453A-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B453D-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B452B-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B4538-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B4539-363D-11E5-9242-09173F13E4C5